Scarica l'app Stockscreener
2.92
1.68%
-0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GDRX Giù?
Forum
Previsione
Precedente Chiudi:
$2.97
Aprire:
$2.94
Volume 24 ore:
1.99M
Relative Volume:
0.89
Capitalizzazione di mercato:
$988.93M
Reddito:
$796.85M
Utile/perdita netta:
$30.44M
Rapporto P/E:
34.68
EPS:
0.0842
Flusso di cassa netto:
$93.88M
1 W Prestazione:
+10.19%
1M Prestazione:
+27.51%
6M Prestazione:
+3.91%
1 anno Prestazione:
-23.36%
Intervallo 1D:
$2.88
$3.005
Intervallo di 1 settimana:
$2.655
$3.005
Portata 52W:
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
Nome
Goodrx Holdings Inc
Settore
Industria
Telefono
(855) 268-2822
Indirizzo
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, TEM, HQY, HNGE
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
2.92 | 1.01B | 796.85M | 30.44M | 93.88M | 0.0842 |
VEEV
Veeva Systems Inc
|
174.34 | 26.83B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
61.68 | 11.80B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
50.47 | 9.21B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
87.99 | 7.59B | 1.31B | 215.20M | 408.32M | 2.4627 |
HNGE
Hinge Health Inc
|
56.21 | 4.25B | 646.34M | -512.40M | 202.76M | -6.6871 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-27 | Downgrade | JP Morgan | Overweight → Neutral |
| 2026-01-22 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-09 | Iniziato | Barclays | Underweight |
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Iniziato | Mizuho | Neutral |
| 2024-08-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-08-10 | Aggiornamento | DA Davidson | Neutral → Buy |
| 2023-07-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Iniziato | Citigroup | Buy |
| 2022-11-04 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-08-12 | Iniziato | DA Davidson | Neutral |
| 2022-06-10 | Downgrade | Goldman | Buy → Neutral |
| 2022-06-06 | Ripresa | BofA Securities | Buy |
| 2022-06-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Iniziato | Wells Fargo | Equal Weight |
| 2022-04-07 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Neutral |
| 2022-03-15 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Reiterato | Barclays | Overweight |
| 2022-03-01 | Reiterato | BofA Securities | Neutral |
| 2022-03-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-01 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Reiterato | Evercore ISI | Outperform |
| 2022-03-01 | Reiterato | Goldman | Buy |
| 2022-03-01 | Reiterato | JP Morgan | Underweight |
| 2022-03-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-03-01 | Reiterato | SVB Leerink | Outperform |
| 2022-01-07 | Iniziato | Goldman | Buy |
| 2021-12-21 | Iniziato | Stephens | Overweight |
| 2021-12-02 | Iniziato | Jefferies | Buy |
| 2021-08-31 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Iniziato | Robert W. Baird | Neutral |
| 2021-04-06 | Ripresa | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Guggenheim | Buy |
| 2020-11-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Iniziato | Barclays | Equal Weight |
| 2020-10-19 | Iniziato | BofA Securities | Neutral |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-10-19 | Iniziato | Credit Suisse | Outperform |
| 2020-10-19 | Iniziato | Deutsche Bank | Hold |
| 2020-10-19 | Iniziato | Goldman | Neutral |
| 2020-10-19 | Iniziato | JP Morgan | Neutral |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
| 2020-10-19 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Iniziato | SVB Leerink | Outperform |
| 2020-10-19 | Iniziato | UBS | Buy |
Mostra tutto
Goodrx Holdings Inc Borsa (GDRX) Ultime notizie
GoodRx (NASDAQ: GDRX) director grant adds 4,642 deferred stock units - Stock Titan
GoodRx (NASDAQ: GDRX) director receives 4,642 deferred stock units - Stock Titan
How The Shifting Story For GoodRx (GDRX) Is Reshaping Analyst Views And Valuation - Yahoo Finance
GoodRx launches $14.99 monthly healthcare subscription service - Investing.com UK
GoodRx (GDRX) Introduces New Monthly Subscription Service - GuruFocus
GoodRx (GDRX) Launches Subscription Plan for Affordable Healthca - GuruFocus
New $14.99 GoodRx membership bundles free meds and $19 telehealth - Stock Titan
GoodRx Holdings Q3 2025 Earnings Preview - MSN
SA analyst upgrades/downgrades: NVDA, META, GDRX, JPM - Seeking Alpha
Hims & Hers Deepens Personalized Care Through Platform Expansion - TradingView
GoodRx: Evident Stabilization, But GLP-1 Dependence Is A Risk (Upgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx (GDRX) Q1 earnings: Taking a look at key metrics versus estimates - MSN
GoodRx Holdings (GDRX) price target increased by 10.24% to 3.17 - MSN
The 5 Most Interesting Analyst Questions From GoodRx’s Q1 Earnings Call - Yahoo Finance
GoodRx (GDRX) CAO exercises RSUs and delivers shares to cover taxes - Stock Titan
GoodRx (NASDAQ: GDRX) executive exercises 44,779 RSUs, 19,726 shares for taxes - Stock Titan
GoodRx Holdings' (NASDAQ:GDRX) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
GDRX Maintained by Citigroup -- Price Target Raised to $4.00 - GuruFocus
GoodRx Holdings Is Maintained at Buy by Citigroup - Moomoo
Jim Cramer on GoodRx: “I’m Going to Grant You That Spec” - Insider Monkey
Some May Be Optimistic About GoodRx Holdings' (NASDAQ:GDRX) Earnings - simplywall.st
GDRX (NASDAQ: GDRX) Form 144 — 43,100-share proposed sale - Stock Titan
Why Jim Cramer Says 'Pull The Trigger' On Chevron - Benzinga
GoodRx (GDRX) awards 54,494 RSUs to Chief Accounting Officer Thomas Chan - Stock Titan
Earnings call transcript: GoodRx Q1 2026 beats revenue forecast, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: GoodRx Q1 2026 beats revenue forecast, stock rises - Investing.com Nigeria
TradingKey - TradingKey
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and DaVita (DVA) - The Globe and Mail
GDRX Maintained by TD Cowen -- Price Target Raised to $4.00 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in Revenue - The Motley Fool
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q1 2026 Earnings Call Transcript - Insider Monkey
GoodRx Earnings Call Highlights Pharma Direct Momentum - TipRanks
GoodRx (GDRX) Q1 2026 Earnings Call Transcript - The Globe and Mail
GoodRx (GDRX) Reports Strong Q1 2026 Earnings and Raises Guidance - GuruFocus
GoodRx Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts - Investing.com India
GoodRx Holdings, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Goodrx Holdings Inc Azioni (GDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.37%
4.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):